Developer site: The content shown here is test data.

MyEClinic
MyEClinic
Health Dictionary AI Health Chat Find an Online Doctor
A serene Zen garden with raked sand and smooth stones, symbolising clarity and calm

Health Dictionary

Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.

Back to skin conditions

Parkinson's disease MRI

Introduction

Overview

Overview

MRI findings in Parkinson disease are: reduction in T2 relaxation time and reduced iron content in putamen and GPe.

We can also use MRI to differentiate PD from other conditions. for example in the midbrain, thinning of anteroposterior diameter and enlargement of third ventricle in suggestive of supranuclear palsy. Also we can see atrophy of brainstem and cerebellum in multiple system atrophy.

MRI

MRI

  • [Location] MRI may be helpful in the diagnosis of [disease name]. Findings on MRI suggestive of/diagnostic of [disease name] include:
    • [Finding 1]
    • [Finding 2]
    • [Finding 3]
  • Diagnosis of Parkinson disease is mostly clinical but there are some MRI finding supporting the diagnosis.
  • In the STN of PD patients there are increased amount of iron. The excess iron will cause a reduction in T2 relaxation time and it’s more prominent in one side.[1] There are also evidence of reduced iron content in putamen and GPe.[2][3]
  • We can also use MRI to differentiate PD from other conditions. for example in the midbrain, thinning of anteroposterior diameter and enlargement of third ventricle in suggestive of supranuclear palsy.[4][5]
  • Also we can see atrophy of brainstem and cerebellum in multiple system atrophy.[6][7]
References

References

  1. ↑ Kosta P, Argyropoulou MI, Markoula S, Konitsiotis S (January 2006). “MRI evaluation of the basal ganglia size and iron content in patients with Parkinson’s disease”. J. Neurol. 253 (1): 26–32. doi:10.1007/s00415-005-0914-9. PMID 15981079.
  2. ↑ Graham JM, Paley MN, Grünewald RA, Hoggard N, Griffiths PD (December 2000). “Brain iron deposition in Parkinson’s disease imaged using the PRIME magnetic resonance sequence”. Brain. 123 Pt 12: 2423–31. PMID 11099445.
  3. ↑ Ryvlin P, Broussolle E, Piollet H, Viallet F, Khalfallah Y, Chazot G (June 1995). “Magnetic resonance imaging evidence of decreased putamenal iron content in idiopathic Parkinson’s disease”. Arch. Neurol. 52 (6): 583–8. PMID 7763206.
  4. ↑ Stern MB, Braffman BH, Skolnick BE, Hurtig HI, Grossman RI (November 1989). “Magnetic resonance imaging in Parkinson’s disease and parkinsonian syndromes”. Neurology. 39 (11): 1524–6. PMID 2812334.
  5. ↑ Asato R, Akiguchi I, Masunaga S, Hashimoto N (2000). “Magnetic resonance imaging distinguishes progressive supranuclear palsy from multiple system atrophy”. J Neural Transm (Vienna). 107 (12): 1427–36. doi:10.1007/s007020070006. PMID 11458995.
  6. ↑ Konagaya M, Konagaya Y, Iida M (December 1994). “Clinical and magnetic resonance imaging study of extrapyramidal symptoms in multiple system atrophy”. J. Neurol. Neurosurg. Psychiatry. 57 (12): 1528–31. PMC 1073237. PMID 7798985.
  7. ↑ Yekhlef F, Ballan G, Macia F, Delmer O, Sourgen C, Tison F (February 2003). “Routine MRI for the differential diagnosis of Parkinson’s disease, MSA, PSP, and CBD”. J Neural Transm (Vienna). 110 (2): 151–69. doi:10.1007/s00702-002-0785-5. PMID 12589575.

Editor-In-Chief:
C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D.